Abstract: The present disclosure relates to a diagnostic classification device and method and, in particular, can provide a diagnostic classification device and method, which can provide an accurate diagnosis with only existing gene expression level measurement technology by extracting an expressed gene specifically expressed from gene expression level information about a patient and classifying a diagnosis name by using the expression level of the extracted expressed gene and artificial intelligence.

Abstract: The present invention provides a peptide nucleic acid probe including any one or more selected from the group consisting of nucleic acid sequences represented by SEQ ID NOs: 7-10 and nucleic acid sequences complementary to the nucleic acid sequences, and manufactured so as to complementarily bind to a BCR/ABL negative myeloproliferative neoplasm-associated gene, thereby enabling multiplex detection of gene mutations; a composition for multiplex detection of gene mutations comprising the same; a kit; and a method for multiplex detection of BCR/ABL negative myeloproliferative neoplasm-associated gene mutations using the same. Therefore, since multiplex detection of BCR/ABL negative myeloproliferative neoplasm-associated gene mutations can be rapidly and accurately carried out by one detection process, BCR/ABL negative myeloproliferative neoplasm is effectively diagnosed, and thus the present invention can be useful for diagnosis, follow-up, prognosis estimation, and treatment of diseases.

Abstract: The present invention provides a peptide nucleic acid probe including any one or more selected from the group consisting of nucleic acid sequences represented by SEQ ID NOs: 7-10 and nucleic acid sequences complementary to the nucleic acid sequences, and manufactured so as to complementarily bind to a BCR/ABL negative myeloproliferative neoplasm-associated gene, thereby enabling multiplex detection of gene mutations; a composition for multiplex detection of gene mutations comprising the same; a kit; and a method for multiplex detection of BCR/ABL negative myeloproliferative neoplasm-associated gene mutations using the same. Therefore, since multiplex detection of BCR/ABL negative myeloproliferative neoplasm-associated gene mutations can be rapidly and accurately carried out by one detection process, BCR/ABL negative myeloproliferative neoplasm is effectively diagnosed, and thus the present invention can be useful for diagnosis, follow-up, prognosis estimation, and treatment of diseases.